Ting-I Lin1, Yung-Feng Huang2, Po-Yen Liu1, Chin-An Chou1, Yu-Shen Chen3, Ying-Yao Chen1, Kai-Sheng Hsieh1, Yao-Shen Chen4. 1. Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC. 2. Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. Electronic address: yf5012@hotmail.com. 3. Department of Internal Medicine, Kaohsiung Veterans General Hospital Pingtung Branch, Pingtung, Taiwan, ROC. 4. Section of Infectious Diseases, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
Abstract
BACKGROUND: Infective endocarditis (IE) due to Pseudomonas aeruginosa is rare and accounts for only about 3% of all patients with this disease. Most infections are associated with the use of intravenous drugs. Patients with P. aeruginosa-related IE who do not use intravenous drugs are extremely rare. We carried out a review of the literature to identify the nature and risk factors of this disease. METHODS: Patients with IE reported between 1993 and 2013 were reviewed by searching the Medline database using the keywords "endocarditis" and "Pseudomonas aeruginosa". All of the patients included met the definition of the modified Duke criteria. RESULTS: Twenty-seven patients in 22 reports were reviewed. IE associated with health care accounted for 20 patients (74%). The mean age of the patients was 53.4 years and there was a predominance of men (81.5%). Native valve endocarditis was seen in 20 (74.1%) patients. Surgery for infection control was performed in 15 (55.6%) patients and the mortality rate in patients who underwent surgery was 33.3% (five patients). A relapse of IE after adequate treatment was seen in nine (33.3%) patients. The mortality rate in all 27 patients was 28.6% (2/7) for those with community-acquired IE and 40% (8/20) for those with IE associated with health care. Univariate analysis showed a higher mortality rate in patients aged >60 years and in those whose source of endocarditis was related to a prosthetic device. CONCLUSION: P. aeruginosa endocarditis has substantial morbidity and mortality. It is characterized by easy relapse and is highly associated with prosthetic devices.
BACKGROUND: Infective endocarditis (IE) due to Pseudomonas aeruginosa is rare and accounts for only about 3% of all patients with this disease. Most infections are associated with the use of intravenous drugs. Patients with P. aeruginosa-related IE who do not use intravenous drugs are extremely rare. We carried out a review of the literature to identify the nature and risk factors of this disease. METHODS:Patients with IE reported between 1993 and 2013 were reviewed by searching the Medline database using the keywords "endocarditis" and "Pseudomonas aeruginosa". All of the patients included met the definition of the modified Duke criteria. RESULTS: Twenty-seven patients in 22 reports were reviewed. IE associated with health care accounted for 20 patients (74%). The mean age of the patients was 53.4 years and there was a predominance of men (81.5%). Native valve endocarditis was seen in 20 (74.1%) patients. Surgery for infection control was performed in 15 (55.6%) patients and the mortality rate in patients who underwent surgery was 33.3% (five patients). A relapse of IE after adequate treatment was seen in nine (33.3%) patients. The mortality rate in all 27 patients was 28.6% (2/7) for those with community-acquired IE and 40% (8/20) for those with IE associated with health care. Univariate analysis showed a higher mortality rate in patients aged >60 years and in those whose source of endocarditis was related to a prosthetic device. CONCLUSION: P. aeruginosa endocarditis has substantial morbidity and mortality. It is characterized by easy relapse and is highly associated with prosthetic devices.
Authors: Andrey Ethan Rubin; Osman Berk Usta; Rene Schloss; Martin Yarmush; Alexander Golberg Journal: Adv Wound Care (New Rochelle) Date: 2019-04-03 Impact factor: 4.730
Authors: Juan Lacalzada-Almeida; Maria Manuela Izquierdo-Gomez; Amelia Duque-Gonzalez; Maria Del Mar Alonso-Socas; Rebeca Munoz-Rodriguez Journal: J Med Cases Date: 2022-06-11
Authors: Jonathan D Edgeworth; Domenico Merante; Sanjay Patel; Christopher Young; Paul Jones; Seema Vithlani; Duncan Wyncoll; Peter Roberts; Andrew Jones; Tsutae Den Nagata; Mari Ariyasu; David M Livermore; Richard Beale Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079